Akebia Therapeutics receives Nasdaq deficiency notice over minimum bid price violation
Bitget2026/10/23 20:07- Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026, for breaching the minimum bid price requirement.
- Its common stock closed below $1.00 for 30 consecutive business days; the notice has no immediate effect on its listing.
- The initial 180-day compliance period ends April 19, 2027; compliance requires closing bids of at least $1.00 for 10 consecutive business days.
- A conditional 180-day extension requires meeting other listing standards and written intent to cure the deficiency through a reverse stock split if necessary.
- Failure to qualify for an extension or restore compliance by its end would trigger a delisting notice, subject to appeal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
